RAD51C, RAD51D and BARD1 (like ATM and CHEK2) would be classified as ‘moderate risk’ BC genes based on the average risks.15 However, according to the BOADICEA predictions, over half (56%–59%) of carriers of PVs in these genes in the population would be reclassified from being in the moderate BC risk category to either being near-population risk (34%–44%) or high risk (15%–22%), if data on the other RFs were incorporated (online supplemental table S1). This evidence concerns the gene BARD1 and breast cancer.